Protein Expression and Cell Line Development Services in CAP and CAP-T Cells
Proteins or vaccines manufactured in our amniocyte derived human CAP cell lines show substantial advantages in post-translational modifications compared to other systems.
Authentic human glycosylation patterns and the absence of immunogenic glycan structures for proteins produced in CAP are an enabling milestone for large scale manufacturing of safe biotherapeutics including vaccines.
CEVEC is pleased to extend the current CAP and CAP-T cell line license offerings by a new cell line development service. The service combines CEVEC‘s CAP cell line with optimized vector construction, serum-free cell line generation and process development using a customized CAP medium.
The service also includes the optional transient production of research material in CAP-T cells for proof of concept studies. Since identical and highest product qualities are provided by CAP and CAP-T, the costly and time-consuming switch from transient to stable cell expression systems like the 293/CHO switch during preclinical development can be avoided. Transiently produced protein from CAP-T can be obtained for PoC studies within just 10 days and facilitates the decision process for stable cell line development significantly.
Further details can be downloaded as pdf file here.
You’re also welcome to contact email@example.com regarding further questions or to receive a quote.